



US 20050220760A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0220760 A1**

Scott et al.

(43) **Pub. Date: Oct. 6, 2005**

(54) **NOVEL IMMUNOTHERAPY**

(52) **U.S. Cl.** **424/85.1; 424/85.2; 514/8; 514/23; 514/54; 424/185.1**

(75) Inventors: **Thomas R. Scott**, Central, SC (US);
Heather P. Borick, Clemson, SC (US);
Ginger A. Swire-Clark, Easley, SC (US);
William R. Marcotte JR., Pendleton, SC (US);
Ashby B. Bodine, Clemson, SC (US)

(57) **ABSTRACT**

Correspondence Address:

DORITY & MANNING, P.A.
POST OFFICE BOX 1449
GREENVILLE, SC 29602-1449 (US)

Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes $\alpha\beta1$ integrin receptors and/or $\alpha\beta4$ integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 $\alpha3$ chain that has been shown to bind $\alpha\beta1$ integrin receptors and $\alpha\beta4$ integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 $\alpha3$ chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

(73) Assignee: **Clemson University**

(21) Appl. No.: **10/817,423**

(22) Filed: **Apr. 2, 2004**

Publication Classification

(51) **Int. Cl.⁷** **A61K 38/19; A61K 38/20; A61K 39/395; A61K 39/00**